1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.
For the quarter period ended December 31, 1996
OR
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.
For the transition period from ______ to ______
Commission File Number: 0-10640
COLLAGEN CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 94-2300486
- ---------------------- ----------------------------------
State of Incorporation I.R.S. Employer Identification No.
2500 Faber Place, Palo Alto, California 94303
Telephone: (415) 856-0200
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
As of January 31, 1997, Registrant had outstanding 8,766,077 shares of common
stock, exclusive of 1,947,900 shares held by the Registrant as treasury stock.
2
COLLAGEN CORPORATION
INDEX
PART I. Financial Information Page No.
- ----------------------------------- --------
Consolidated Balance Sheets -
December 31, 1996 and June 30, 1996. . . . . . . . . . . . . . . . . . . . . 3
Consolidated Statements of Income -
Three and six months ended December 31, 1996 and 1995. . . . . .. . . . . . .4
Consolidated Statements of Cash Flows -
Six months ended December 31, 1996 and 1995 . . . . . . . . . . . . . . . . .5
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . 6-9
Management's Discussion and Analysis of Financial
Condition and Results of Operations . . . . . . . . . . . . . . . . . . .10-18
PART II. Other Information
- -------------------------------
Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . .19-22
Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23
2
3
COLLAGEN CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share amounts)
December 31, June 30,
1996 1996 *
---------------- ----------------
ASSETS
Current assets:
Cash and cash equivalents $ 16,052 $ 21,676
Short-term investments 6,641 3,691
Accounts receivable, net 10,314 9,508
Inventories, net 11,826 9,563
Other current assets, net 9,102 11,496
---------------- ----------------
Total current assets 53,935 55,934
Property and equipment, net 15,900 15,147
Intangible assets and goodwill, net 14,047 14,824
Investment in Target Therapeutics, Inc. 53,587 65,841
Other investments & assets, net 14,086 11,261
---------------- ----------------
$ 151,555 $ 163,007
================ ================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 3,029 $ 3,824
Other accrued liabilities 12,333 11,869
Income taxes payable 4,779 7,588
Notes payable 5,075 5,079
---------------- ----------------
Total current liabilities 25,216 28,360
Long-term liabilities:
Deferred income taxes 23,859 27,674
Other long-term liabilities 3,973 3,444
Minority interest 326 528
---------------- ----------------
Total long-term liabilities 28,158 31,646
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, authorized: 5,000,000 shares;
none issued and outstanding --- ---
Common stock, $.01 par value, authorized: 28,950,000 shares,
issued: 10,672,879 shares at December 31, 1996 (10,575,614
shares at June 30, 1996), outstanding: 8,724,979 shares at
December 31, 1996 (8,775,614 shares at June 30, 1996) 107 106
Additional paid-in capital 65,906 64,844
Retained earnings 44,827 42,378
Cumulative translation adjustment (919) (656)
Unrealized gain on available-for-sale investments 29,026 34,549
Treasury stock, at cost, 1,947,900 shares at December 31, 1996
(1,800,000 shares at June 30, 1996) (40,766) (38,220)
---------------- ----------------
Total stockholders' equity 98,181 103,001
---------------- ----------------
$ 151,555 $ 163,007
================ ================
* Amounts derived from audited financial statements.
3
4
COLLAGEN CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended Six Months Ended
December 31, December 31,
-------------------------- ---------------------------
1996 1995 1996 1995
----------- ---------- ---------- -----------
Revenues:
Product Sales $ 19,057 $ 18,883 $ 35,842 $ 33,823
Other --- --- --- 2,000
----------- ---------- ---------- -----------
19,057 18,883 35,842 35,823
----------- ---------- ---------- -----------
Costs and expenses:
Cost of sales 5,321 5,074 10,466 9,071
Selling, general and administrative 10,479 10,467 19,328 18,769
Research and development 4,525 2,925 8,686 5,504
Acquired in-process research and development --- --- --- 14,800
----------- ---------- ---------- -----------
20,325 18,466 38,480 48,144
----------- ---------- ---------- -----------
Income (loss) from operations (1,268) 417 (2,638) (12,321)
Other income (expense):
Net gain on investments, principally
Target Therapeutics, Inc. 3,038 20,921 9,222 31,387
Equity in earnings (losses) of affiliates, net (123) 415 (597) (93)
Interest income 305 297 660 451
Interest expense (146) (40) (231) (52)
----------- ---------- ---------- -----------
Income before income taxes and minority interest 1,806 22,010 6,416 19,372
Provision for income taxes 957 12,540 3,400 18,453
Minority interest (162) --- (302) ---
----------- ---------- ---------- -----------
Net income $ 1,011 $ 9,470 $ 3,318 $ 919
=========== ========== ========== ===========
Net income per share $ .11 $ 1.05 $ .37 $ .10
=========== ========== ========== ===========
Shares used in calculating per share information 8,841 9,059 8,963 9,087
=========== ========== ========== ===========
4
5
COLLAGEN CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
Increase (Decrease) in Cash and Cash Equivalents
(Unaudited)
(In thousands)
Six Months Ended
December 31,
------------------------------
1996 1995
------------------------------
Cash flows from operating activities:
Net income $ 3,318 $ 919
Adjustments to reconcile net income to net cash provided by
(used in) operating activities:
Acquired in-process research and development -- 14,800
Depreciation and amortization 3,107 2,968
Equity in losses of affiliates 597 93
Gain on investments, net of taxes paid of $5.2 million and (4,051) (14,502)
$16.9 million, respectively
Other adjustments related to changes in
assets and liabilities (4,776) 2,787
------------- ----------
Net cash provided by (used in) operating activities (1,805) 7,065
------------- ----------
Cash flows from investing activities:
Proceeds from sale of Target Therapeutics, Inc. stock, net of taxes paid 5,578 25,188
Proceeds from sales and maturities of short-term investments 1,675 3,123
Purchases of short-term investments (4,625) (1,318)
Expenditures for property and equipment (2,989) (1,332)
Increase in intangible and other assets (99) (458)
Expenditures for investments in and loans to affiliates (1,491) (6,198)
Acquisition of LipoMatrix, Incorporated, net of cash balances -- (22,608)
Accrued purchase consideration and other costs of
acquisition of LipoMatrix -- 22,527
------------- ------------
Net cash provided by (used in) investing activities (1,951) 18,924
------------- ------------
Cash flows from financing activities:
Repurchase of common stock (2,546) (3,034)
Net proceeds from issuance of common stock 1,063 41
Cash dividends paid (885) (676)
Net borrowing under bank loans 500 70
------------- ------------
Net cash used in financing activities (1,868) (3,599)
------------- ------------
Net increase (decrease) in cash and cash equivalents (5,624) 22,390
Cash and cash equivalents at beginning of period 21,676 6,155
------------- ------------
Cash and cash equivalents at end of period $ 16,052 $ 28,545
============= ============
5
6
COLLAGEN CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Summary of Significant Accounting Policies
Basis of Presentation
The consolidated financial statements include the accounts of Collagen
Corporation (the "Company"), a Delaware corporation, and its wholly-owned
and majority-owned subsidiaries. All significant intercompany accounts and
transactions have been eliminated. The Company operates in one industry
segment focusing on the development, manufacturing and sale of medical
devices. Investments in unconsolidated subsidiaries, and other investments
in which the Company has a 20% to 50% interest or otherwise has the ability
to exercise significant influence, are accounted for under the equity
method. Investments in companies in which the Company has less than 20%
interest with no readily determinable fair value are carried at cost or
estimated realizable value, if less, and those with a readily determinable
fair value are carried at market value.
The consolidated balance sheet as of December 31, 1996, the consolidated
statements of income for the three and six months ended December 31, 1996
and 1995, and the consolidated statements of cash flows for the six months
ended December 31, 1996 and 1995, have been prepared by the Company,
without audit. In the opinion of management, all necessary adjustments
(which include only normal recurring adjustments) have been made to present
fairly the financial position, results of operations and cash flows at
December 31, 1996 and for all periods presented. Interim results are not
necessarily indicative of results for a full fiscal year. The consolidated
balance sheet as of June 30, 1996 has been derived from the audited
consolidated financial statements at that date.
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted. These consolidated financial
statements should be read in conjunction with the audited consolidated
financial statements and notes thereto for the year ended June 30, 1996
included in the Company's Annual Report on Form 10-K for the year ended
June 30, 1996.
New Accounting Standard
In October 1995, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 123, Accounting for Stock-Based
Compensation ("SFAS#123"), which establishes a fair value method of
accounting for stock options and other equity instruments. The Company
adopted SFAS#123 beginning in fiscal year 1997 and will use the disclosure
method as described in the statement. The required disclosure will be
included in the Company's Annual Report on Form 10-K for the year ended
June 30, 1997.
6
7
2. Inventories
Inventories consist of the following (in thousands):
December 31, June 30,
1996 1996
-------------- ---------------
Raw materials $ 1,090 $ 1,148
Work-in-process 4,456 3,630
Finished goods 6,280 4,785
-------------- ---------------
$ 11,826 $ 9,563
============== ===============
3. Investment in Target Therapeutics, Inc. (Boston Scientific, Inc.)
The Company accounts for its investment in Target Therapeutics ("Target")
under the cost method as an available-for-sale equity security, which is
carried at market value. During the three and six months ended December 31,
1996, the Company sold 100,000 shares and 330,000 shares, respectively, of
Target common stock for a pre-tax gain of approximately $3.0 million and
$9.2 million, respectively. Target's common stock is quoted on The Nasdaq
Stock Market. The closing price of Target's stock at December 31, 1996 was
$42.00 per share. At December 31, 1996, the Company held 1,275,888 shares
of Target's common stock, or approximately a 9% ownership position in
Target.
At June 30, 1996 and December 31, 1996, the Company's shares of Target
common stock were recorded at the estimated fair value of $65.8 million and
$53.6 million, respectively. The $58.4 million unrealized gain ($65.8
million estimated fair value less $7.4 million cost) at June 30, 1996, and
the $47.7 million unrealized gain ($53.6 million estimated fair value less
$5.9 million cost) at December 31, 1996, on these available-for-sale
securities has been reported as a separate component of stockholders'
equity, net of tax.
On January 20, 1997, Boston Scientific Corporation (of Natick,
Massachusetts) and Target jointly announced the signing of a definitive
agreement to merge in a tax-free stock-for-stock transaction. Under the
merger agreement, Target's stockholders will receive 1.07 shares of Boston
Scientific Corporation ("Boston Scientific") common stock in exchange for
each share of Target common stock. The merger is expected to close during
the second calendar quarter of 1997. Assuming the planned merger is
completed, the Company's 1,275,888 shares of Target's common stock will be
exchanged for approximately 1,365,200 shares of Boston Scientific.
Additionally, the Company may be unable to sell additional Boston
Scientific/Target shares during the next six to nine months due to
accounting, and tax matters and other restrictions pertaining to the
merger.
Boston Scientific is a leading manufacturer of catheter-based devices that
can be inserted through small body openings and are used in heart surgery
and other operations. Boston Scientific common stock is quoted on the New
York Stock Exchange under the symbol BSX.
7
8
Its closing price on January 31, 1997 was $68.25 per share.
4. Investment in Innovasive Devices, Inc.
Prior to October 1996, the Company's 844,000 shares of common stock of
Innovasive Devices, Inc. ("Innovasive Devices") were valued at cost or
$4,064,000 due to restrictions which prevented the sale of any of the
Company's shares of common stock of Innovasive Devices. Effective October
1996, restrictions were no longer applicable on approximately 473,000
shares of common stock which the Company holds in Innovasive Devices. As a
result, the Company now carries the non-restricted portion of its
investment in Innovasive Devices at market value or $3.7 million,
reflecting an unrealized gain of $1.4 million, which has been included in a
separate component of stockholders' equity, net of tax. The remaining
371,000 restricted shares of common stock continue to be valued at cost.
During the three and six months ended December 31, 1996, the Company did
not sell any of its shares of common stock of Innovasive Devices.
Innovasive Devices' common stock is quoted on The Nasdaq Stock Market. The
closing price of Innovasive Devices' common stock at December 31, 1996, was
$7.75 per share. At December 31, 1996, the Company held approximately a 12%
ownership position in Innovasive Devices.
5. Stock Repurchase Program
In February 1993, the Company's Board of Directors authorized a stock
repurchase program. Since the inception of the stock repurchase program in
February 1993, the Company has repurchased 1,947,900 shares of its common
stock at an average acquisition price of approximately $21 per share.
During the six months ended December 31, 1996, 147,900 shares were
repurchased and as of such date, the Company is authorized to repurchase an
additional 352,100 shares under the program. The Company currently plans to
keep the repurchased shares as treasury stock and may use this stock in
various company stock benefit plans.
6. Income Taxes
The provision for income taxes for the six months ended December 31, 1996
and 1995, was computed by applying the estimated annual income tax rates of
approximately 53% and 54% (excluding the impact of the acquired in-process
R&D charge for which no tax benefit was available), respectively, to income
before income taxes. The lower effective tax rate in the current year was
primarily a result of lower projected annual losses from foreign
subsidiaries.
8
9
7. Per Share Information
Net income per share for the three and six months ended December 31, 1996
and 1995, have been computed based upon the weighted average number of
common stock and dilutive common stock equivalent shares outstanding.
Shares used in the per share computations are as follows (in thousands):
Three Months Ended Six Months
Ended Ended
December 31, December 31,
---------------------- -----------------------
1996 1995 1996 1995
-------- -------- -------- --------
Primary:
Common stock 8,690 8,916 8,827 8,954
Stock options 151 143 136 133
-------- -------- -------- --------
Weighted average number of common
stock and dilutive common stock
shares equivalent shares outstanding 8,841 9,059 8,963 9,087
======== ======== ======== ========
9
10
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Except for the historical information contained herein, the matters discussed in
this report are forward=looking statements that involve certain risks and
uncertainties that could cause actual results to differ materially from those in
the forward=looking statements. Potential risks and uncertainties include,
without limitation, those mentioned in this report and, in particular the
factors described below under "Factors That May Affect Future Results of
Operations" as well as those under the same heading in the Company's Annual
Report on Form 10=K for the fiscal year ended June 30, 1996.
The Company
Collagen Corporation (the "Company") is a technology=based company that
develops, manufactures and markets biomedical devices for the treatment of
defective, diseased, traumatized or aging human tissues.
The Company's revenues are derived primarily from the sale of products
principally used in reconstructive and cosmetic applications for the face and
breast, the treatment of stress urinary incontinence, and in bone repair. The
Company markets its reconstructive and cosmetic products directly and through a
network of international distributors and its stress urinary incontinence and
bone repair products through marketing partners.
In addition to internal research and development ("R&D") and joint product
development arrangements, the Company has an active program for developing new
products through affiliated companies in which the Company makes equity and debt
investments. The Company believes the formation of new companies allows each to
focus its technology on select market segments to bring products to market
efficiently and to expand its proprietary knowledge.
Aesthetic Technologies(TM) and Collagen Technologies Groups
The Board of Directors and management have reviewed various strategic
alternatives to improve the market's recognition of the intrinsic value of the
Company. As a result, the Company announced on January 8, 1997, that it will
formally separate the Aesthetic Technologies(TM) Group, its profitable aesthetic
and reconstructive surgery business, and form a new company, Aesthetic
Technologies(TM) Corporation. Aesthetic Technologies Corporation will focus on
developing its profitable aesthetic and reconstructive surgery business with
strong and growing product offerings that encompass many new exciting
technologies in aesthetic medicine. Management and the Board of Directors will
continue to evaluate strategies for Aesthetic Technologies Corporation, which
may include a public offering, a "spin=off" or a "split=off", among other
alternatives. The timing and nature of these actions will depend upon tax,
legal, market and other considerations.
10
11
The Company's other business activities consist primarily of the Collagen
Technologies Group, which develops novel collagen and polymer materials, as well
as internal and affiliate company=sponsored product development programs in the
fields of orthopedics, soft=tissue repair, vascular surgery and ophthalmology.
The Collagen Technologies Group also manufactures and sells Collagraft(R) bone
graft matrix and Collagraft(R) bone graft matrix strip ("Collagraft bone graft
products") to the Company's marketing partner, Zimmer, Inc. ("Zimmer"), a
division of Bristol Myers=Squibb Company. In addition, Collagen Technologies
Group holds equity investments in and product development and supply agreements
with four privately held affiliates and equity investments in two public
companies, Target Therapeutics, Inc. ("Target") and Innovasive Devices, Inc.
("Innovasive Devices").
The planned formation of Aesthetic Technologies Corporation does not affect the
presentation of the Company's financial results presented for the three and six
months ended December 31, 1996.
Results of Operations
The following tables show for the periods indicated the percentage relationship
to product sales of certain items in the Consolidated Statements of Income.
PERCENT OF PRODUCT SALES
Three Months Ended Six Months Ended
December 31, December 31,
------------------ -----------------
1996 1995 1996 1995
---- ---- ---- ----
Product sales 100% 100% 100% 100%
Other revenues -- -- -- 6%
Costs and expenses:
Cost of sales 28% 27% 29% 27%
Selling, general and administrative 55% 55% 54% 56%
Research and development 24% 16% 24% 16%
Product sales. Product sales of $19.1 million in the three months ended December
31, 1996, increased approximately $.2 million or 1%, compared to product sales
of $18.9 million for the same prior-year period. Product sales of $35.8 million
in the six months ended December 31, 1996, increased approximately $2.0 million
or 6%, compared to product sales of $33.8 million for the same prior-year
period. The increase in sales for the six months ended December 31, 1996, was
primarily due to the increase in international sales of plastic surgery and
dermatological products (which includes injectable collagen products,
Trilucent(TM) breast implant ("Trilucent"), and Hylaform(R) viscoelastic gel
("Hylaform gel") ) and an increase in revenue from direct sales of Contigen(R)
implant ("Contigen") to physician customers by C.R. Bard, Inc. ("Bard"), the
Company's marketing partner for Contigen. (See "Operating income/loss" below.)
11
12
Worldwide sales of plastic surgery and dermatological products for the three and
six months ended December 31, 1996, were $16.8 million and $30.9 million, up 4%
and 7%, from sales of $16.1 million and $29.0 million, respectively, for the
same periods in the prior year. The increase in sales for the three and six
months ended December 31, 1996, was a result of sales growth in all plastic
surgery and dermatological product lines. The Company believes that the sales
growth in injectable collagen products in the current fiscal quarter and year
was a result of continued growth in distributor sales, increased demand by
consumers for a wide variety of aesthetic procedures and continued physician
interest in cosmetic procedures not reimbursed by third-party payers. The
Company anticipates continued dollar growth in future worldwide product sales in
these markets.
Worldwide unit sales of plastic surgery and dermatological products for the
three and six months ended December 31, 1996, increased approximately 11% and
12% over the same periods in the prior year. Domestically, implementation of
United States marketing programs designed to increase average treatment volume
per patient and to attract and retain new and existing patients, have favorably
impacted overall unit sales, but have unfavorably impacted realized revenue per
unit of product sold. The addition of Hylaform gel, which was launched in Europe
in November 1996, has also favorably impacted overall unit sales.
During the three and six months ended December 31, 1996, pursuant to terms of an
agreement between the Company and Bard, the Company recorded revenue of $1.7
million and $3.2 million, respectively, from Bard based on Bard's direct sales
of Contigen to physician customers. In June 1995, the Company announced that it
expected to ship little, if any, Contigen to Bard due to excess inventory at
Bard. The Company recorded minimal revenue from shipments of Contigen to Bard in
the three and six months ended December 31, 1996, and December 31, 1995. Future
revenue from shipments of Contigen to Bard is expected to resume in the fourth
quarter of fiscal 1997.
For the three and six months ended December 31, 1996, sales of Collagraft(R)
bone graft matrix and Collagraft(R) bone graft matrix strip ("Collagraft bone
graft products") to the Company's marketing partner, Zimmer, Inc. ("Zimmer"),
were approximately $290,000 and $1.0 million, respectively, compared to $844,000
and $1.8 million in the same periods in the prior year. The decrease in sales in
the current fiscal year period was due to lower than expected sales by Zimmer
and a consequent decrease in shipments from the Company. The Company expects
sales and shipments of Collagraft bone graft products for fiscal 1997 to be less
than those recorded during fiscal 1996.
A number of uncertainties exist surrounding the marketing and distribution of
Contigen and Collagraft bone graft products. The Company's primary means of
distribution for these products is through third party firms, Bard in the case
of Contigen and Zimmer in the case of Collagraft bone graft products. The
Company's business and financial results could be adversely affected in the
event that either or both of these parties are unable to market the products
effectively, anticipate customer demand accurately, or effectively manage
industry-wide pricing and cost containment pressures in health care.
Other revenues. Other revenues in the six months ended December 31, 1995
consisted of a final milestone payment of $2 million from Bard in accordance
with an agreement between the Company and Bard.
12
13
Cost of sales. Cost of sales as a percentage of product sales was 28% and 29%
for the three and six months ended December 31, 1996, compared with 27% for both
periods in the prior year. The higher cost of sales as a percentage of product
sales in the current fiscal quarter and year was primarily a result of the
change in product mix (i.e., Trilucent and Hylaform gel) which has resulted in
higher costs per unit.
Due to the high fixed costs of the Company's Fremont, California manufacturing
facility, unit cost of manufacturing for collagen-based injectable products is
expected to remain highly dependent on the level of output at the Company's
manufacturing facility and continued demand for the collagen-based injectable
product lines. The Company anticipates that overall unit costs will be slightly
lower in fiscal 1997 compared to fiscal 1996.
SG&A. Selling, general and administrative ("SG&A") expenses were $10.5 million
in the three months ended December 31, 1996, which were unchanged from the same
prior-year period. SG&A expenses of $19.3 million in the six months ended
December 31, 1996, increased approximately $.5 million or 3%, compared to SG&A
expenses of $18.8 million for the same prior-year period. The increase in SG&A
expenses in the current fiscal year period resulted primarily from the inclusion
of six months of SG&A expenses of LipoMatrix, Incorporated ("LipoMatrix"), the
developer and manufacturer of Trilucent, and amortization expenses on purchased
intangibles and goodwill resulting from the acquisition of LipoMatrix compared
to four months for the same period in the prior year. SG&A expenses as a
percentage of product sales were 55% and 54% for the three and six months ended
December 31, 1996, compared to 55% and 56% for the same periods in the prior
year. The decrease in SG&A expenses as a percentage of product sales in the
current year period was primarily due to lower sales and marketing launch costs
for Trilucent combined with an increase in product sales. The Company expects
its SG&A expenses to increase slightly over the next several quarters,
approximately 1 to 2 percent per quarter, as a result of the expenses involved
in exploring and evaluating strategies for the new company, Aesthetic
Technologies Corporation.
R&D. Research and development ("R&D") expenses, which include expenditures for
regulatory compliance, were $4.5 million and $8.7 million (24% of product sales)
for the three and six months ended December 31, 1996, an increase of 55% and 58%
over $2.9 million and $5.5 million (16% of product sales), for the same periods
in the prior year. The increase in R&D spending in the current fiscal year
period was primarily attributable to the inclusion of six months of LipoMatrix
R&D expenses compared to four months for the same period in the prior year, the
inclusion of R&D expenses for Cohesion Corporation as a result of the Company
increasing its ownership percentage to 81% in June 1996 and the costs associated
with the commencement of Trilucent clinical trials in the United States and
Europe. The Trilucent clinical trials in the United States and Europe are
expected to take several years and may involve multiple product design changes
and clinical studies. The Company expects internal R&D spending in fiscal 1997
to be at levels higher than fiscal 1996 due to the inclusion of expenses of
Cohesion Corporation and a full year of expenses for LipoMatrix.
Acquired in-process research and development. The charge for acquired in-process
research and development ("in-process R&D") of $14.8 million in the six months
ended December 31, 1995, was a non-recurring charge related to the acquisition
of LipoMatrix. The value attributed to in-process R&D was determined by an
independent appraisal. Substantial effort, including clinical trials and
regulatory approval, still is required before Trilucent can be marketed in the
United States.
13
14
Operating income/loss. Operating loss was $1.3 million for the three months
ended December 31, 1996, compared with an operating income of $417,000 for the
same prior-year period. The Company's consolidated operating loss was $2.6
million for the six months ended December 31, 1996, compared with a $12.3
million loss for the same prior-year period. The loss in the current fiscal year
was primarily due to the inclusion of six months of LipoMatrix operating
expenses compared to four months for the same period in the prior year, the
inclusion of the operating results of Cohesion Corporation, the costs associated
with commencing Trilucent clinical trials in the United States and Europe and
costs incurred to increase the manufacturing capacity for Trilucent implant. The
Company's consolidated $12.3 million operating loss for the six months ended
December 31, 1995, was primarily due to the $14.8 million acquisition-related,
non-recurring R&D charge related to LipoMatrix.
Compared with foreign exchange rates for the same prior-year quarter, the impact
of foreign exchange rates in the current fiscal quarter on operating income was
a net increase of $156,000 on equivalent local currency basis, resulting from a
decrease of approximately $251,000 in operating expenses, partially offset by a
decrease of approximately $95,000 in revenue. Compared with foreign exchange
rates for the same prior-year period, the impact of foreign exchange rates in
the current fiscal year on operating income was a net increase of $181,000 on
equivalent local currency basis, resulting from a decrease of approximately
$323,000 in operating expenses, partially offset by a decrease of approximately
$142,000 in revenue. Until December 1994, the Company's policy was to hedge
material foreign currency transaction exposures. At June 30, 1996 and December
31, 1996, no foreign currency transaction exposures were hedged. Unhedged net
foreign assets were $14.5 million and $17.0 million at June 30, 1996 and
December 31, 1996, respectively.
Gain on investments, net. In the three months ended December 31, 1996, the
Company recorded a gain on investments of $3.0 million ($1.3 million after taxes
of $1.7 million), resulting from the sale of 100,000 shares of Target
Therapeutics, Inc. ("Target") common stock. In the six months ended December 31,
1996, the Company recorded a gain on investments of $9.2 million ($4.0 million
after taxes of $5.2 million), resulting from the sale of 330,000 shares of
Target common stock. As the planned merger between Boston Scientific and Target
is completed, the Company may be unable to sell additional Boston
Scientific/Target shares during the next six to nine months due to accounting
and tax matters and other restrictions pertaining to the merger.
Equity in earnings/losses of affiliate companies. Equity in losses of affiliate
companies was approximately $123,000 for the three months ended December 31,
1996, compared to equity in losses of approximately $415,000 for the same
prior-year quarter. For the six months ended December 31, 1996, equity in losses
of affiliate companies was $597,000, compared with losses of $93,000 in the same
prior-year period.
The Company intends to continue to expand its new product development activities
through more equity investments in or loans to affiliate companies during fiscal
year 1997. These affiliate companies typically are in an early stage of
development and may be expected to incur substantial losses, which in turn will
have an adverse effect on the Company's operating results. There can be no
assurance that these investments will result in positive returns nor can there
be any assurance on the timing of any return on investment, or that the Company
will not lose its entire investment.
14
15
Interest income. Interest income was $305,000 and $660,000 for the three and six
months ended December 31, 1996, respectively, compared with $297,000 and
$451,000 for the same periods in the prior year. The increase in the current
fiscal year was primarily due to higher average short-term investment balances,
resulting primarily from the sale of Target stock.
Income tax. The provision for income taxes for the six months ended December 31,
1996 and 1995, was computed by applying the estimated annual income tax rates of
approximately 53% and 54% (excluding the impact of the acquired in-process R&D
charge for which no tax benefit was available), respectively, to income before
income taxes. The lower effective tax rate in the current year was primarily a
result of lower projected annual losses from foreign subsidiaries.
Liquidity and Capital Resources
At December 31, 1996, the Company's cash, cash equivalents and short-term
investments were $22.7 million compared to $25.4 million at June 30, 1996. Net
cash used in operating activities was approximately $1.8 million in the six
months ended December 31, 1996, compared to approximately $7.1 million of net
cash provided by operating activities for the same prior-year period.
The $1.8 million of net cash used in operating activities in the six months
ended December 31, 1996, was mainly attributable to a $2.8 million decrease in
income taxes payable resulting from estimated payments made related to the sales
of Target stock, a $2.3 million increase in inventory, a $.8 million increase in
accounts receivable, a $.3 million decrease in accounts payable and accrued
liabilities, a $.3 million unfavorable foreign currency translation impact, a
$.2 million decrease in the minority interest liability, partially offset by
$2.9 million of net income after adjusting for depreciation and amortization
expense, equity in losses (earnings) and gain on investments (net of taxes paid)
and a $2.0 million decrease in miscellaneous receivables related to the sales of
Target stock.
The $3.8 million of net cash used in investing and financing activities in the
six months ended December 31, 1996, was primarily due to payments of $4.6
million to purchase short-term investments, capital expenditures of
approximately $3.0 million, payments of approximately $2.5 million to repurchase
147,900 shares of the Company's common stock at an average acquisition price of
approximately $17.00 per share, payments of approximately $1.5 million for
additional investments in affiliates, and payment of cash dividends of
approximately $.9 million to the Company's stockholders in July 1996, partially
offset by proceeds of $5.6 million net of taxes paid ($10.8 million proceeds
less taxes paid of $5.2 million ) from the sale of 330,000 shares of common
stock of Target by the Company during the year, $1.7 million proceeds received
from the sale of short-term investments, and $1.1 million from the issuance of
approximately 97,000 shares of the Company's common stock.
The Company anticipates capital expenditures, equity investments in, and loans
to affiliate companies to be approximately $12 million in fiscal 1997. As of
December 31, 1996, the Company's capital expenditures, equity investments in,
and loans to affiliate companies totaled approximately $4.5 million. In November
1996, the Company's Board of Directors declared a cash dividend of 10 cents per
share to stockholders of record on December 16, 1996. This dividend totaled
approximately $869,000 and was paid to stockholders on January 15, 1997. The
Company anticipates that the Board of Directors will review the possibility of
declaring an
15
16
additional dividend before the end of the current fiscal year. Additionally, in
June 1996, the Board of Directors authorized the Company to repurchase an
additional 500,000 shares of the Company's common stock in the open market, of
which the Company has repurchased 147,900 shares as of December 31, 1996.
The Company's principal sources of liquidity include cash generated from
operations, sales of Target stock, and its cash, cash equivalents and short-term
investments. During the fiscal quarter ended September 30, 1994, the Company's
Board of Directors authorized the Company to sell portions of its holdings of
Target's common stock. Between July 1, 1994 and December 31, 1996, the Company
sold an aggregate of 3,312,500 shares of Target common stock (adjusted for a
two-for-one stock split in December 1995) for an aggregate pre-tax gain of
approximately $101.1 million ($116.6 million proceeds less cost basis of $15.5
million). At December 31, 1996, the Company held 1,275,888 shares of Target's
common stock. The Company anticipates that stock sales pursuant to the
authorization will be made from time to time, under SEC Rule 144, with the
objective of generating cash, for, among other things, further investments in
both current and new affiliate companies. As the planned merger between Boston
Scientific and Target is completed, the Company may be unable to sell additional
Boston Scientific/Target shares during the next six to nine months due to
accounting and tax matters and other restrictions pertaining to the merger.
In addition, the Company established a $7.0 million revolving credit facility
with a bank in November 1994, which was subsequently increased to $15.0 million
in December 1995. As of December 31, 1996, $10.0 million of this credit facility
remained unused. Additionally, the Company has a $3.1 million (4.1 million Swiss
Francs) credit facility that was established by LipoMatrix prior to the
Company's acquisition of LipoMatrix, of which $843,000 (1.1 million Swiss
Francs) remained unused as of December 31, 1996.
The Company's capital requirements will depend on numerous factors, including
market acceptance and demand for the Company's products; the resources the
Company devotes to the development, manufacture and marketing of its products;
the progress of the Company's clinical research and product development
programs; the extent to which the Company enters into collaborative
relationships with third parties and the scope of the Company's obligations in
such relationships; the receipt of, and the time required to obtain, regulatory
clearances and approvals; the resources required to protect the Company's
intellectual property and other factors. The timing and amount of such capital
requirements cannot be accurately predicted. Funds may also be used for the
acquisition of businesses, products and technologies that are complementary to
those of the Company. The Company believes that its current sources of liquidity
should be adequate to fund its anticipated capital requirements through at least
the next 18 months. However, during this period or thereafter, the Company may
require additional financing. There can be no assurance that such additional
financing will be available on terms favorable to the Company or at all.
Factors That May Affect Future Results of Operations
A large portion of the Company's revenues in recent years has come from its
international operations. As a result, the Company's operations and financial
results could be significantly affected by international factors, including
numerous regulatory agencies, changes in foreign currency exchange rates and
foreign economic and political conditions generally. The
16
17
Company's operating strategy takes into account changes in these factors over
time; however, the Company's results of operations could be significantly
affected in the short term by fluctuations in foreign currency exchange rates or
disruptions to shipments.
All of the Company's manufacturing capacity for collagen products, the majority
of its research and development activities, its corporate headquarters, and
other critical business functions are located near major earthquake faults. In
addition, all of the Company's manufacturing capacity for collagen-based
products and Trilucent are located in two primary facilities (one for
collagen-based products and one for Trilucent), with the Company currently
maintaining only limited amounts of finished product inventory. While the
Company has some limited protection in the form of disaster recovery programs
and basic insurance coverage, the Company's operating results and financial
condition would be materially adversely affected in the event of a major
earthquake, fire or other similar calamity, affecting its manufacturing
facilities.
The Company is involved in various legal actions arising in the course of
business, some of which involve product liability and intellectual property
claims. The Company operates in an industry susceptible to claims that may
allege that the use of the Company's technology or products has resulted in
adverse effects or infringes on third-party technology. With respect to product
liability claims, such risks will exist even with respect to those products that
have received or in the future may receive regulatory approval for commercial
sale. It is possible that adverse product liability or intellectual property
actions could negatively affect the Company's future results of operations.
The Company has been and may be in the future the subject of negative publicity,
which can arise from various sources, ranging from the news media on cosmetic
procedures in general to legislative and regulatory investigations specific to
the Company concerning, among other things, the safety and efficacy of its
products. The Company is confident of the safety and effectiveness of its
products; however, there can be no assurance that such investigations or
negative publicity from such investigations or from the news media will not
result in a material adverse effect on the Company's future financial position,
its results of operations or the market price of its stock. In addition,
significant negative publicity could result in an increased number of product
liability claims.
The Company's manufacturing activities and products sold in the United States
are subject to extensive and rigorous regulations by the FDA and by comparable
agencies in certain foreign countries where these products are manufactured or
distributed. The FDA regulates the manufacture and sale of medical devices in
the U.S., including labeling, advertising and record keeping. Failure to obtain,
or delays in obtaining, the required regulatory approvals for new products, as
well as product recalls, both inside and outside of the U.S. could adversely
affect the Company. The Company is conducting Trilucent clinical trials in
Europe and the United States, which are expected to take several years and may
involve multiple product design changes and clinical studies.
Due to the factors noted above, as well as other factors that may affect the
Company's operating results, the Company's future earnings and stock price may
be subject to significant volatility, particularly on a quarterly basis. Any
shortfall in revenue or earnings from levels expected by securities analysts
could have an immediate and significant adverse effect on the trading price of
the Company's common stock in any given period. Additionally, the Company may
not learn of, or be able to confirm, such shortfalls until late in the fiscal
quarter, or following the end of the quarter, which could result in an even more
immediate and adverse effect on the
17
18
trading price of the Company's common stock. Finally, the Company participates
in a highly dynamic industry, which often results in significant volatility of
the Company's common stock.
For a more complete discussion of risks and uncertainties involving the
Company's business, please see the risks factors described under the heading
"Factors That May Affect Future Results of Operations" set forth in the
Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1996.
18
19
PART II. OTHER INFORMATION
COLLAGEN CORPORATION
Item 1. Legal Proceedings
On December 21, 1994, the Company filed suit against Matrix
Pharmaceutical, Inc., ("Matrix") alleging fraud, misappropriation of
trade secrets, unfair competition, breach of fiduciary duty, inducing
breach of contract, breach of duty of loyalty and tortious
interference. The Company alleges that Matrix, which uses collagen for
certain drug delivery applications, unlawfully obtained the Company's
confidential and proprietary information relating to Collagen's
products and operations by hiring ten former employees that the
Company alleges had access to or were knowledgeable about the
Company's proprietary information. On February 12, 1995, Matrix denied
the Company's allegations and filed a cross-complaint charging the
Company with, among other things, unfair competition, defamation and
restraint of trade. Matrix also has requested certain declaratory
relief. Howard Palefsky, the Company's Chairman of the Board and Chief
Executive Officer, was personally named as an additional defendant to
the Matrix defamation charge. On September 24, 1996, a Demurrer and
Motion to Strike Matrix's third amended complaint was sustained in
Collagen's favor, dismissing Matrix's anti-trust and common law
restraint of trade claims. A trial date has been scheduled for April
7, 1997. Collagen and Matrix currently are engaged in discovery.
Item 2. Changes in Securities
None
Item 3. Defaults Upon Senior Securities
None
Item 4. Submission of Matters to a Vote of Security Holders
A. On October 30, 1996, the Registrant held its Annual Meeting of
Stockholders.
B. As listed below, all of management's nominees for directors were
elected at the meeting pursuant to proxies solicited pursuant to
Regulation 14 under the Securities and Exchange Act of 1934 (in
thousands).
19
20
No. of No. of No of No of No of
Votes Votes Votes Votes Broker Non-
Name of Nominee For Against Withheld Abstained Votes
- --------------- --- ------- -------- --------- -----
Reid W. Dennis 7,697 0 492 0 0
Howard D. Palefsky 7,692 0 497 0 0
Anne L. Bakar 7,697 0 492 0 0
John R. Daniels, MD 7,679 0 510 0 0
William G. Davis 7,698 0 491 0 0
Craig W. Johnson 7,697 0 492 0 0
Rodney Perkins, MD 7,678 0 511 0 0
Gary S. Petersmeyer 7,675 0 514 0 0
Roger H. Salquist 7,694 0 495 0 0
C. The adoption of an amendment to the 1994 Stock Option Plan to
increase the number of shares of common stock reserved for
issuance thereunder by 400,000 shares was approved with
5,096,210 shares voting in favor, 2,948,817 shares voting
against and 55,520 shares abstaining.
D. The appointment of Ernst & Young LLP as independent auditors of
the Company for the fiscal year ending June 30, 1997 was
ratified with 8,118,886 shares voting in favor, 57,820 voting
against and 12,543 shares abstaining.
Item 5. Other Information
On February 10, 1997, the Board of Directors made the following
appointments: Gary Petersmeyer was appointed Chief Executive Officer
of Collagen Corporation in addition to retaining the title of
President, succeeding Howard D. Palefsky who will remain as Chairman
of the Board of Directors; David Foster was promoted to Senior Vice
President of Collagen Corporation and General Manager of Collagen
Technologies Group; Norman Halleen was appointed Vice President,
Finance and Chief Financial Officer and Jean-Pierre CapDevielle was
appointed Vice President and Managing Director, International.
20
21
Item 6. Exhibits and Reports on Form 8-K
A. Exhibits
Exhibit 3.4 - By-Laws, as amended on August 9, 1996, effective
October 30, 1996
Exhibit 10.67(e) - Eighth Amendment, dated December 31, 1996, to
Credit Agreement dated November 15, 1994 by and between the Bank of
New York and the Registrant
Exhibit 10.86 * - License, Supply and International Distribution
Agreement between Registrant and Cosmederm Technologies, Inc., dated
September 6, 1996
Exhibit 27 - Financial Data Schedule
B. Reports on Form 8-K
None
- --------
* Confidential treatment is requested for a portion of this document.
21
22
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COLLAGEN CORPORATION
Date: February 13, 1997 /s/ Norman Halleen
----------------- ------------------
Norman Halleen
Vice President, Finance and
Chief Financial Officer
(Principal Financial
and Accounting Officer)
23
COLLAGEN CORPORATION
INDEX TO EXHIBITS
Exhibit Number Description
- -------------- -----------
Exhibit 3.4 By-Laws, as amended on August 9, 1996, effective
October 30, 1996
Exhibit 10.67(e) Eighth Amendment, dated December 31, 1996, to Credit
Agreement dated November 15, 1994 by and between the
Bank of New York and the Registrant
Exhibit 10.86* License, Supply and International Distribution
Agreement between Registrant and Cosmederm
Technologies, Inc., dated September 6, 1996
Exhibit 27 Financial Data Schedule
- --------
* Confidential treatment is requested for a portion of this document.
22